Expression profiling of budding cells in colorectal cancer reveals an EMT-like phenotype and molecular subtype switching
Open accessAbstract
BACKGROUND: Tumour budding, described as the presence of single cells or small clusters of up to five tumour cells at the invasive margin, is established as a prognostic marker in colorectal carcinoma. In the present study, we aimed to investigate the molecular signature of tumour budding cells and the corresponding tumour bulk. METHODS: Tumour bulk and budding areas were microdissected and processed for RNA-sequencing. As little RNA was obtained from budding cells, a special low-input mRNA library preparation protocol was used. Gene expression profiles of budding as compared with tumour bulk were investigated for established EMT signatures, consensus molecular subtype (CMS), gene set enrichment and pathway analysis. RESULTS: A total of 296 genes were differentially expressed with an FDR <0.05 and a twofold change between tumour bulk and budding regions. Genes that were upregulated in the budding signature were mainly involved in cell migration and survival while downregulated genes were important for cell proliferation. Supervised clustering according to an established EMT gene signature categorised budding regions as EMT-positive, whereas tumour bulk was considered EMT-negative. Furthermore, a shift from CMS2 (epithelial) to CMS4 (mesenchymal) was observed as tumour cells transit from the tumour bulk to the budding regions. CONCLUSIONS: Tumour budding regions are characterised by a phenotype switch compared with the tumour bulk, involving the acquisition of migratory characteristics and a decrease in cell proliferation. In particular, most tumour budding signatures were EMT-positive and switched from an epithelial subtype (CMS2) in the tumour bulk to a mesenchymal subtype (CMS4) in budding cells.
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The CMS4 subtype is associated with tumor budding.
“several studies have documented an association between the CMS4 subtype and tumor budding, defined as a single tumor cell or tumor cluster of up to four cells at the invasive margin (29–31)”
From Clinical Challenges of Consensus Molecular Subtype CMS4 Colon Cancer in the Era of Precision Medicine (2024) · cites this paper as [30]
The CMS4 tumor state arises from the progression of a less aggressive state, rather than originating from a distinct carcinogenesis pathway, perhaps with the exception of inflammation-induced colorectal cancer.
“Altogether, several works based on paired tumor regions (11, 19, 30) support the notion that the CMS4 tumor state arises from the progression of a less aggressive state, rather than originating from a distinct carcinogenesis pathway, perhaps with the exception of inflammation-induced colorectal cancer (25).”
From Clinical Challenges of Consensus Molecular Subtype CMS4 Colon Cancer in the Era of Precision Medicine (2024) · cites this paper as [30]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
The citation lists haven’t been fetched yet
References 41 · Cited by 163
- Authors
- De Smedt, L., Palmans, S., Andel, D., Govaere, O., Boeckx, B., Smeets, D., Galle, E., Wouters, J., Barras, D., Suffiotti, M., Dekervel, J., Tousseyn, T., De Hertogh, G., Prenen, H., Tejpar, S., Lambrechts, D., & Sagaert, X.
- Affiliations
- KU Leuven (BE)
- Vlaams Instituut voor Biotechnologie (BE)
- SIB Swiss Institute of Bioinformatics (CH)
- Universitair Ziekenhuis Leuven (BE)
- Corresponding author
- Sagaert, Xavier
- ORCID
- Venue
- British Journal of Cancer
- Published
- 2016-11-24
- Volume
- 116
- Issue
- 1
- Pages
- 58-65
- ISSN
- 0007-0920 (ISSN-L)
- 1532-1827
- PMC
- PMC5220148
- OpenAlex
- W2551519849
- Cited by
- 163
- References
- 41
- Citations by year
- 2026: 7 · 2025: 13 · 2024: 17 · 2023: 25 · 2022: 18 · 2021: 21 · 2020: 20 · 2019: 21 · 2018: 15 · 2017: 6
- FWCI
- 7.54
- Type
- journal article
- Language
- en
- Open access
- hybrid
- doi.org
- Licence
- Locations
- British Journal of Cancer (publishedVersion, cc-by-nc-sa)
- Europe PMC (PubMed Central) (publishedVersion, cc-by-nc-sa)
- PubMed Central (publishedVersion, cc-by-nc-sa)
- PubMed (publishedVersion)
- Lirias (submittedVersion, other-oa)
- Newcastle University ePrints (Newcastle Univesity)
- Funders
- Vlaams Supercomputer Centrum
- KU Leuven (PFV/10/016 SymBioSys, PFV/10/016)
- Vlaamse regering
- Departement Economie, Wetenschap en Innovatie
- Topics
- Health Sciences › Medicine › Oncology › Cancer Cells and Metastasis
- Health Sciences › Medicine › Oncology › Colorectal Cancer Treatments and Studies
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Mechanisms of cancer metastasis
- Keywords
- tumor budding, colorectal cancer, epithelial-mesenchymal transition, consensus molecular subtypes, gene expression profiling, tumor microenvironment, cell migration, cell proliferation, low-input RNA sequencing
- MeSH terms
- Margins of Excision, Adult, Aged, Aged, 80 and over, Cell Division, Female, Genes, Switch, Humans, Male, Middle Aged, Neoplasm Invasiveness, Phenotype, Colorectal Neoplasms, Gene Expression Profiling, Tissue Array Analysis, Cell Proliferation, Epithelial-Mesenchymal Transition, Transcriptome
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review